4 results
8-K
EX-99.1
ALGS
Aligos Therapeutics, Inc.
5 Aug 21
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
4:06pm
and NASH drug candidates,” commented Lawrence Blatt, PhD, MBA, Chairman and CEO of Aligos. “At recent scientific conferences, healthy volunteer data from
10-K
2020 FY
ALGS
Aligos Therapeutics, Inc.
23 Mar 21
Annual report
4:26pm
in patients with CHB.
In the healthy volunteer portion of the study, where enrollment was completed, ALG‑000184 was orally administered once (SAD
S-1/A
EX-3.2
ALGS
Aligos Therapeutics, Inc.
9 Oct 20
IPO registration (amended)
5:26pm
patient is dosed in the healthy volunteer arm of the Corporation’s multiple ascending dose study for S-Antigen Transport-Inhibiting Oligonucleotide
S-1
EX-3.1
ALGS
Aligos Therapeutics, Inc.
25 Sep 20
IPO registration
5:27pm
; or following the earlier of (i) September 30, 2021 or (ii) the date that the last patient is dosed in the healthy volunteer arm of the Corporation’s
- Prev
- 1
- Next